NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs

Lecanemab, the first drug to slow Alzheimer's progression, approved by UK regulator but deemed too expensive for NHS use.

• Lecanemab shown to slow cognitive decline by 27% in early-stage Alzheimer's patients.
• NICE cites high costs and modest benefits in decision against NHS coverage.
• The drug requires intensive monitoring and bi-weekly infusions, adding to the expense.
• Approximately 70,000 patients in England would have been eligible for treatment.
• Alzheimer's charities urge government intervention to ensure equitable access.

33 Articles

The Telegraph The Telegraph The Independent BBC The Japan Times Boston Globe The Telegraph The Independent The Independent Benzinga Sky News The Telegraph Evening Standard Boston Globe Evening Standard Denver Gazette Evening Standard The Independent Evening Standard Open Access Government The Independent The Independent The Independent Associated Press BBC Evening Standard The Independent Evening Standard Stat News The Telegraph Sky News Nature The Telegraph